FATE THERAPEUTICS INC - 10-Q Filing

Fate Therapeutics reports Q3 financial results including research and development expense updates and milestone-related disclosures.

SEC EDGAR ·

Tickers: $FATE

Read the full article at SEC EDGAR

More Regulatory news